Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.40 |
| ▸ | HSPA8 | P11142 | 1/20 | 0.40 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RBP4 | P02753 | 5/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 10/20 | 0.36 |
| ▸ | HTR2B | P41595 | 10/20 | 0.36 |
| ▸ | HTR2A | P28223 | 8/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4482441 | 0.84 | ALDH1A1 (0.48) | ALDH1A1 | |
| SCHEMBL4473055 | 0.84 | ALDH1A1 (0.48) | ALDH1A1 | |
| SCHEMBL4473052 | 0.84 | ALDH1A1 (0.48) | ALDH1A1 | |
| SCHEMBL4493838 | 0.84 | ALDH1A1 (0.48) | ALDH1A1 | |
| SCHEMBL4494774 | 0.81 | DDB1 (0.34) | ALDH1A1MEN1KMT2APDE7AHTR2C | |
| SCHEMBL13637321 | 0.80 | ALDH1A1 (0.43) | ALDH1A1KMT2A | |
| SCHEMBL4492914 | 0.80 | ALDH1A1 (0.43) | ALDH1A1KMT2A | |
| SCHEMBL4481729 | 0.80 | ALDH1A1 (0.43) | ALDH1A1KMT2A | |
| SCHEMBL13627302 | 0.80 | ALDH1A1 (0.43) | ALDH1A1KMT2A | |
| SCHEMBL4492909 | 0.80 | ALDH1A1 (0.43) | ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618980-B2 | Pyrrolo(oxo)quinolines as 5HT ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-17 | — | — | US | disclosed |
| US-20060014778-A1 | (+-)-cis 6-Methoxy-8-phenyl-2,3,3a,4,5,9b-hexahydro-1H-pyrrolo[3,4-c]quinoline; serotonin receptor modulators; obesity, diabetes, atherosclerosis, dyslipidemia; central nervous system diseases like anxiety, depression, OCD, panic disorder, psychosis, schizophrenia, sleep and sexual disorders, | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014778-A1 | (+-)-cis 6-Methoxy-8-phenyl-2,3,3a,4,5,9b-hexahydro-1H-pyrrolo[3,4-c]quinoline; serotonin receptor modulators; obesity, diabetes, atherosclerosis, dyslipidemia; central nervous system diseases like anxiety, depression, OCD, panic disorder, psychosis, schizophrenia, sleep and sexual disorders, | HTR3B, HTR2C, HTR2B | ALDH1A1 3212/4885MEN1 2995/4885HSPA1A 4296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.